secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001654954-22-006657
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q2 net loss $4.57M ($0.33/shr) on lower R&D spend; clinical trials advancing
--------------------------------------------------------------------------------

- Net loss $4.57M for quarter ended Mar 31, 2022 vs $2.26M year ago; R&D expenses fell $4.94M to $3.04M.
- Six-month net loss $8.95M ($0.66/shr) vs $4.90M ($0.45/shr); raised ~$11.6M via ATM and direct investment.
- Working capital $14.66M; cash and equivalents $15.89M at quarter end.
- Phase 3 ARDS trial >25% randomized; approvals in Canada, Poland, Colombia; U.S. design discussions ongoing.
- Phase 2b allergic contact dermatitis study 75% enrolled; completion expected Q4 2022, topline data early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/0001654954-22-006657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495422006657/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-22-006657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer